The immunogenotypic criteria of forecast of joints diseases development

106 patients with axial spondylarthritis (SpA), 98 patients with knee joints osteoarthritis (OA) and 136 patients with rheumatoid arthritis (RA) are included in research. At all patients are investigated polymorphism of cytokines genes TNFА (rs361525, rs1800629 rs1800630), IL1β (rs1143627), IL4 (rs2243250), IL6 (rs1800795), IL10 (rs1800872, rs1800872), IL17(rs2275913, rs763780), vascular endothelial growth factor gene VEGF (rs3025039, rs699947), matrix metalloproteinases genes MMP2 (rs2438650), MMP3 (rs3025058), MMP9 (rs3918242). Genetic attributes which meet various frequency among patients with RA and which are never revealed in group of SpA or OA patients, and alternative attributes which in one case are not revealed among patients with RA, and frequently come to light among patients with SpA or OA are allocated. These attributes alternativeness allows to use them with a high degree of reliability as additional laboratory criteria of the differential diagnosis at early stages of joints diseases development.

1. Kłak A., Paradowska-Gorycka A., Kwiatkowska B., Raciborski F. Personalized medicine in rheumatology. Reumatologia. 2016;54(4): 177–86. DOI: 10.5114/reum.2016.62472.

2. Savoia C., Volpe M., Grassi G., Borghi C., Agabiti Rosei E., Touyz R.M. Personalized medicine — a modern approach for the diagnosis and management of hypertension. Clin. Sci. (Lond). 2017; 131(22):2671–85. DOI: 10.1042/CS20160407.

3. Konenkov V.I., Poveshchenko O.V., Prokofiev V.F., Shevchenko A.V., Kim I.N., Bondarenko N.A. et al. The analysis of clinical, functional, laboratory and genetic parameters values on the condition of patients after myocardial infarction, and prognosis of intramyocardial autologic cell therapy effectiveness for chronic heart failure. Kardiovaskulyarnaya terapiya i profilaktika. 2015;14(1):23–9. DOI: 10.15829/1728-8800-2015-1-23-29. (In Russian).

4. Shevchenko A.V., Prokofyev V.F., Korolev M.A., Banshchi kova N.E., Konenkov V.I. Polymorphism in the regulatory regions -С2578A and +C936T of the vascular endothelial growth factor (VEGF-A) gene in Russian women with rheumatoid arthritis. Terapevticheskii Arkhiv. 2017;89(5):60–4. DOI: 10.17116/terarkh201789560-64. (in Russian)

5. Chernykh V., Shevchenko A., Konenkov V., Prokofiev V., Eremina A., Trunov A. TNF-α gene polymorphisms: association with age-related macular degeneration in Russian population. Int. J. Ophthalmol. 2019;12(1):25–9. DOI: 10.18240/ijo.2019.01.04

6. Weir B. Genetic data analysis. Methods for discrete population genetic data. Moscow: Mir; 1995. (in Russian)

7. Babich P.N., Chubenko A.V., Lapach S.N. Application of modern statistical methods in clinical trials. Part 3. Odds ratio: Concept, Computation and Interpretation. Ukrainskii Medicinskii Zurnal. 2005;46(2):113–19. (in Russian)

8. Lloyd C.J., Moldovan M.V. Exact one-sided confidence bounds for the risk ratio in 2 x 2 tables with structural zero. Biom. J. 2007;49(6): 952–63. DOI: 10.1002/bimj.200710357

9. Glantz S. Primer of biostatistics. Moscow: Praktika, 1998. (in Russian)

10. Cuppen B.V., Welsing P.M., Sprengers J.J., Bijlsma J.W., Marijnissen A.C., van Laar J.M. et al. Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability. Rheumatology. (Oxford). 2016;55(5):826–39. DOI: 10.1093/rheumatology/kev421.

11. Bayley J.P., Ottenhoff T.H., Verweij C.L. Is there a future for TNF promoter polymorphisms? Genes. Immun. 2004;5(5):315–29. DOI: 10.1038/sj.gene.6364055.

12. Wang L.Q., Sun W., Wang Y., Li D., Hu A.M. Downregulation of plasma miR-124 expression is a predictive biomarker for prognosis of glioma. Eur. Rev. Med. Pharmacol. Sci. 2019;23(1):271–76. DOI: 10.26355/eurrev_201901_16773.

13. Antman E.M., Loscalzo J. Precision medicine in cardiology. Nat. Rev. Cardiol. 2016;13(10):591–602. DOI: 10.1038/nrcardio.2016.101.